Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VBIO
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
— | — | — | 0.15 |
+8 more quarters Free account |
Revenue Growth |
— | — | — | 15.87% | |
Cost of Revenue |
— | — | — | 0.29 | |
Gross Profit |
— | — | — | (0.14) | |
R&D Expenses |
2.70 | 1.85 | 1.28 | 0.86 | |
SG&A Expenses |
3.72 | 3.78 | 1.22 | 1.48 | |
Operating Income |
(6.42) | (5.63) | (2.21) | (2.48) | |
Non-operating Interest Expenses |
0.69 | 0.65 | 0.15 | 0.00 | |
Non-operating Income/Expense |
(0.63) | (0.59) | 0.01 | (0.11) | |
| (7.06) | (6.22) | (2.35) | (2.60) | ||
Income after Tax |
(7.06) | (6.22) | (2.35) | (2.60) | |
Dividends (Preferred) |
0.25 | 0.24 | 0.18 | — | |
Net Income Common |
(7.35) | (6.44) | (3.03) | (2.60) | |
EPS (Basic) |
(54.25) | (55.75) | (22.21) | (49.25) | |
EPS (Diluted) |
(54.25) | (55.75) | (22.21) | (49.25) | |
Shares (Basic, Weighted) |
0.14 | 0.12 | 0.05 | 0.05 | |
Shares (Diluted, Weighted) |
0.14 | 0.12 | 0.05 | 0.05 | |
Gross Margin |
— | — | — | (99.32%) | |
EBIT Margin |
0.00% | 0.00% | 0.00% | (1,700.68%) | |
EBT margin |
0.00% | 0.00% | 0.00% | (1,778.08%) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (1,778.08%) | |
EBITDA |
(5.33) | (5.01) | (2.11) | (2.48) | |
EBIT |
(6.42) | (5.63) | (2.36) | (2.48) | |
Income from Continuous Operations |
(7.06) | (6.22) | (2.35) | (2.60) | |
Income from Discontinued Operations |
(0.05) | 0.02 | (0.50) | — | |
Consolidated Net Income/Loss |
(7.10) | (6.20) | (2.85) | (2.60) | |
EPS (Basic, from Continuous Ops) |
(52.20) | (53.97) | (15.99) | (49.14) | |
EPS (Diluted, from Cont. Ops) |
(52.20) | (53.97) | (15.99) | (49.14) | |
EPS (Diluted, from Disc. Ops) |
0.00 | 0.00 | 0.00 | — | |
EPS (Basic, from Discontinued Ops) |
(0.34) | 0.20 | (6.22) | — | |
EPS (Basic, Consolidated) |
(52.54) | (53.77) | (22.21) | (49.14) | |
EPS (Diluted, Consolidated) |
(52.54) | (53.77) | (22.21) | (49.14) | |
Shares (Diluted, Average) |
0.14 | 0.12 | — | 0.05 | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | (1,700.68%) | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | (1,367.12%) |